
Philadelphia-based Longevity Biotech develops Hybridtides, transformative products tackling medical challenges.
Founded in Philadelphia, Longevity Biotech focuses on developing Hybridtides, a new class of therapeutic candidates aimed at addressing some of the most challenging aspects of modern medicine. The company’s core mission is to deliver clinically transformative products, leveraging their breakthrough peptide technology to create unique drug profiles. Their market focus includes preclinical development programs and optimizing oral peptide delivery through proprietary databases.
Notable affiliated individuals and investors include experts in biotechnology and pharmaceuticals, though specific names are not provided. Key achievements include the development of multiple preclinical programs based on their Hybridtide technology. Longevity Biotech's impact lies in its innovative approach to drug development, potentially transforming treatment paradigms for various medical conditions.

Extend Biosciences
extendbio.com

Longeveron
longeveron.com

Longevity InTime BioTech
intime.digital

Juvenescence
juvlabs.com

20n Bio
20n.bio

Extended Longevity

Regenerative Bio
regen-bio.us

Longevica
longevica.com

Mytide Therapeutics

BioAge Labs
bioagelabs.com

Retro Biosciences
retro.bio

Rejuveron Life Sciences
rejuveron.com

Lytica Therapeutics

Cambrian BioPharma
cambrianbio.com

Permeon Biologics
permeonbio.com
Companies similar to Longevity Biotech include Extend Biosciences, Longeveron, Longevity InTime BioTech and Juvenescence.
Longevity Biotech was founded in 2010.
Longevity Biotech's headquarters is located in Philadelphia, PA, US.
Longevity Biotech's most recent funding round was for $316.4k (USD) in November 2017.
As of Nov 9, 2017, Longevity Biotech has raised a total of $1.9M (USD).
Longevity Biotech has 6 employees as of Feb 5, 2024.